ArticlePloS one2026
Integrative pan-resistome and transcriptomic characterization reveals differential gene expression signatures in carbapenem-resistant Acinetobacter baumannii: Insights into efflux pump regulation and therapeutic targeting strategies.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii is a significant, multidrug-resistant pathogen that is increasingly recognized as an agent associated with hospital infections. Its increasing resistance to carbapenems and other necessary antibiotics poses a serious threat to public health worldwide. The present study provides an integrative analysis of the pan-resistome and transcriptomic landscape of carbapenem-resistant A. baumannii (CRAB) under sub-minimum inhibitory concentrations (sub-MICs) of clinically relevant antibiotics, i.e., ciprofloxacin, amikacin sulfate, meropenem, and polymyxin B. A focused investigation was conducted into the transcriptional modulation of efflux transport systems and cellular stress-response mechanisms. To identify differentially expressed genes (DEGs) among the CRAB strains, parallel comparative RNA-Seq analysis with already available public datasets was undertaken. Concurrently, high-throughput virtual screening against the comprehensive marine natural product database (CMNPD) was done to identify inhibitors for MacB, a major ABC-type efflux transporter. Binding stability and interaction profiles of lead compounds were assessed via molecular dynamics simulations of 1000 ns. Transcriptomic profiling consistently showed increased levels of MacA-MacB efflux components, RcnB an intracellular stress-response protein LolA an outer membrane chaperone and surface antigen protein 1, especially under polymyxin B exposure. CMNPD27284 is the best candidate, having a strong binding affinity and stable interaction networks with critical MacB residues (-7.20 kcal/mol). These results highlight that efflux-mediated resistance and stress adaptation are crucial factors in CRAB, and they also indicate CMNPD27284 as a potential candidate for marine-derived scaffolding in developing drugs targeting the efflux pump.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.